TCRYPTION
TCRyption is a preclinical company focused on the development of novel approaches to TCR based cellular therapy for cancer and other indications. TCRyption seeks to develop a pipeline of product candidates that can treat cancer type and patient populations that are underserved by current approaches.
TCRYPTION
Industry:
Biotechnology Health Care
Founded:
2020-10-01
Address:
New York, New York, United States
Country:
United States
Status:
Active
Total Funding:
10 M USD
Similar Organizations
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Prolocor
Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.
Renovacor
Renovacor is a biopharmaceutical company that focuses on developing transformative gene therapy‑based treatments for cardiovascular disease.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Investors List
TIO Bioventures
TIO Bioventures investment in Seed Round - TCRyption
More informations about "TCRyption"
TCRyption - Crunchbase Company Profile & Funding
TCRyption is a preclinical company focused on the development of novel approaches to TCR based cellular therapy for cancer and other indications. TCRyption seeks to develop a pipeline of product candidates that can treat cancer type and patient populations that are underserved by …See details»
Treadwell Therapeutics Announces Acquisition of …
Oct 15, 2021 “By combining Treadwell with TCRyption, we expect to realize substantial operational efficiencies and better leverage our rapidly growing and talented global R&D organization,” added Dr. Shane ...See details»
The Treadwell Story - uhncommercialization.ca
The TCRyption Story. Emerging from the groundbreaking T-cell immunotherapy technologies created by Princess Margaret Hospital’s Senior Scientist Dr. Naoto Hirano, TCRyption was founded by Dr. Hirano and his fellow pioneers in the T …See details»
Treadwell Therapeutics Announces Acquisition of TCRyption
Oct 15, 2021 NEW YORK & HONG KONG--(BUSINESS WIRE)-- Treadwell Therapeutics today announced the acquisition of TCRyption Inc., a company focusing on novel approaches to TCR based T cell therapy and a TIO Bioventures portfolio company.The stock swap brings the unique and powerful TCRypt platform technology as well as a large number of TCR candidates with …See details»
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a …
Oct 19, 2021 Treadwell Therapeutics today announced the acquisition of TCRyption Inc., a company focusing on novel approaches to TCR based T cell therapy and a TIO Bioventures portfolio company. The stock swap brings the unique and powerful TCRypt platform technology as well as a large number of TCR candidates with potential anti-cancer utility into Treadwell’s …See details»
TCRyption - Ownership and Business Overview - Mergr
TCRyption is a preclinical company focused on the development of novel approaches to TCR based cellular therapy for cancer and other indications. TCRyption is based in Toronto, Ontario. Company Summary. SECTOR. Life Science. Investor History; 2021-10-15 Add-on Acquisition. Treadwell TherapeuticsSee details»
TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell
Oct 7, 2020 Founded by Dr. Naoto Hirano and pioneers of the TCR field, Dr. Tak Mak and Dr. Mark Davis, bringing decades of experience and knowledge in cancer therapeutics, TCRyption’s new immunotherapy pipeline is poised to expand treatment options for cancer patients NEW YORK--( BUSINESS WIRE )-- TIO Bioventures today announced the launch of TCRyption …See details»
TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell based ...
Oct 7, 2020 The TIO Discovery engine is a fully functioning organization, featuring drug discovery, R&D and early stage clinical development capabilities that provide deep support for TIO Bioventures ...See details»
TCRyption 2025 Company Profile: Valuation, Investors ... - PitchBook
TCRyption General Information Description. Developer of novel TCR-based T cell therapy designed to rapidly clone physiologically relevant TCRs. The company's platform is used to identify TCRs recognizing a diverse array of epitopes regardless of haplotype with unmatched sensitivity and speed, enabling companies to develop a pipeline of product candidates that …See details»
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a …
Oct 19, 2021 Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel TCR-Based T Cell Therapy Company and TIO Bioventures Portfolio Company. Share: ... large number of TCR candidates with potential anti-cancer utility into Treadwell’s growing and highly productive R&D organization. The platform can be used to identify TCRs recognizing a ...See details»
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a …
Oct 15, 2021 Treadwell Therapeutics today announced the acquisition of TCRyption Inc., a company focusing on novel approaches to TCR based T cell therapy and a TIO. About About EIN Presswire How We Are Different. Better How It Works Testimonials Contact EIN Presswire in …See details»
decryption organization abbr. Crossword Clue | Wordplays.com
Answers for decryption organization abbr. crossword clue, 3 letters. Search for crossword clues found in the Daily Celebrity, NY Times, Daily Mirror, Telegraph and major publications. Find clues for decryption organization abbr. or most any crossword answer or clues for crossword answers.See details»
Decryption organization: Abbr. - Dan Word
Decryption organization: Abbr. Today's crossword puzzle clue is a quick one: Decryption organization: Abbr.. We will try to find the right answer to this particular crossword clue. Here are the possible solutions for "Decryption organization: Abbr." clue. It was last seen in American quick crossword. We have 1 possible answer in our database.See details»
TCRyption - Products, Competitors, Financials, Employees, …
TCRyption is a preclinical company that focuses on the development of TCR-based cellular therapy for cancer and other indications. On October 15, 2021, TCRyption was acquired by Treadwell Therapeutics for an undisclosed amount. Use the CB Insights Platform to explore TCRyption's full profile.See details»
Child exploitation watchdog says Meta encryption led to sharp …
12 hours ago The National Center for Missing and Exploited Children’s annual report said the organization received about 29.2 million reports of suspected exploitation in 2024 — a drop of roughly 19% ...See details»
US decryption organization: Abbr. - Dan Word
US decryption organization: Abbr. Today's crossword puzzle clue is a quick one: US decryption organization: Abbr.. We will try to find the right answer to this particular crossword clue. Here are the possible solutions for "US decryption organization: Abbr." clue. It was last seen in Daily celebrity quick crossword.See details»
Decryption org. - crossword puzzle clue
Recent usage in crossword puzzles: WSJ Daily - May 20, 2023; Universal Crossword - Nov. 22, 2020; LA Times - Oct. 3, 2019; LA Times - June 1, 2016; Newsday - Dec. 29 ...See details»
TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell based ...
Oct 8, 2020 The TIO Discovery engine is a fully functioning organization, featuring drug discovery, R&D and early stage clinical development capabilities that provide deep support for TIO Bioventures companies as they move into further stages of development.See details»
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a …
Oct 16, 2021 Initial TCRyption programs could enter the clinic in early 2023. NEW YORK, NY, USA & HONG KONG, China I October 15, 2021 I Treadwell Therapeutics today announced the acquisition of TCRyption Inc., a company focusing on novel approaches to TCR based T cell therapy and a TIO Bioventures portfolio company. The stock swap brings the unique and ...See details»
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a …
Oct 15, 2021 Treadwell Therapeutics today announced the acquisition of TCRyption Inc., a company focusing on novel approaches to TCR based T cell therapy and a TIO Bioventures portfolio company. The stock swap brings the unique and powerful TCRypt platform technology as well as a large number of TCR candidates with potential anti-cancer utility into Treadwell’s …See details»